Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023755744> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W2023755744 endingPage "588" @default.
- W2023755744 startingPage "581" @default.
- W2023755744 abstract "Angiotensin-converting-enzyme (ACE) inhibitors reduce cardiovascular mortality and morbidity in patients with heart failure or left ventricular systolic dysfunction (LVSD). Three large trials have assessed the effect of ACE inhibitors in stable patients without these conditions but with atherosclerosis. We undertook a systematic review of the Heart Outcomes Prevention Evaluation (HOPE), the European trial on Reduction Of cardiac events with Perindopril among patients with stable coronary Artery disease (EUROPA), and the Prevention of Events with ACE inhibition (PEACE) studies to determine the consistency with which ACE inhibitors reduce total mortality and fatal and non-fatal cardiovascular events.We computed cardiovascular outcomes and total mortality in the 29,805 patients of these three trials, randomly assigned an ACE inhibitor or placebo and followed up for a mean of about 4.5 years. The results were also analysed within the context of five large trials of ACE inhibitors in patients with heart failure or LVSD.When the findings of the HOPE, EUROPA, and PEACE trials were combined, ACE inhibitors significantly reduced all-cause mortality (7.8 vs 8.9%, p=0.0004), cardiovascular mortality (4.3 vs 5.2%, p=0.0002), non-fatal myocardial infarction (5.3 vs 6.4%, p=0.0001), all stroke (2.2 vs 2.8%, p=0.0004), heart failure (2.1 vs 2.7%, p=0.0007), coronary-artery bypass surgery (6.0 vs 6.9%, p=0.0036) but not percutaneous coronary intervention (7.4 vs 7.6%, p=0.481). The composite outcomes of cardiovascular mortality, non-fatal myocardial infarction, or stroke occurred in 1599 (10.7%) of the patients allocated ACE inhibitor and in 1910 (12.8%) of those allocated placebo (odds ratio, 0.82; 95% CIs 0.76-0.88; p<0.0001). Except for stroke and revascularisation, these results were similar to those of the five trials in patients with heart failure or LVSD.ACE inhibitors reduce serious vascular events in patients with atherosclerosis without known evidence of LVSD or heart failure. Results showing these benefits in intermediate-risk patients complement existing evidence of similar benefit in higher-risk patients with LVSD or heart failure. Therefore, use of ACE inhibitors should be considered in all patients with atherosclerosis." @default.
- W2023755744 created "2016-06-24" @default.
- W2023755744 creator A5007737202 @default.
- W2023755744 creator A5018419311 @default.
- W2023755744 creator A5039145780 @default.
- W2023755744 creator A5047726859 @default.
- W2023755744 creator A5060181258 @default.
- W2023755744 date "2006-08-01" @default.
- W2023755744 modified "2023-10-16" @default.
- W2023755744 title "Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials" @default.
- W2023755744 cites W1503037753 @default.
- W2023755744 cites W1592471891 @default.
- W2023755744 cites W180946569 @default.
- W2023755744 cites W1966953116 @default.
- W2023755744 cites W1988569489 @default.
- W2023755744 cites W2008372707 @default.
- W2023755744 cites W2055123579 @default.
- W2023755744 cites W2106244081 @default.
- W2023755744 cites W2157440775 @default.
- W2023755744 cites W2305118939 @default.
- W2023755744 cites W2312388685 @default.
- W2023755744 cites W2469805673 @default.
- W2023755744 cites W2585382523 @default.
- W2023755744 doi "https://doi.org/10.1016/s0140-6736(06)69201-5" @default.
- W2023755744 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16905022" @default.
- W2023755744 hasPublicationYear "2006" @default.
- W2023755744 type Work @default.
- W2023755744 sameAs 2023755744 @default.
- W2023755744 citedByCount "467" @default.
- W2023755744 countsByYear W20237557442012 @default.
- W2023755744 countsByYear W20237557442013 @default.
- W2023755744 countsByYear W20237557442014 @default.
- W2023755744 countsByYear W20237557442015 @default.
- W2023755744 countsByYear W20237557442016 @default.
- W2023755744 countsByYear W20237557442017 @default.
- W2023755744 countsByYear W20237557442018 @default.
- W2023755744 countsByYear W20237557442019 @default.
- W2023755744 countsByYear W20237557442020 @default.
- W2023755744 countsByYear W20237557442021 @default.
- W2023755744 countsByYear W20237557442022 @default.
- W2023755744 countsByYear W20237557442023 @default.
- W2023755744 crossrefType "journal-article" @default.
- W2023755744 hasAuthorship W2023755744A5007737202 @default.
- W2023755744 hasAuthorship W2023755744A5018419311 @default.
- W2023755744 hasAuthorship W2023755744A5039145780 @default.
- W2023755744 hasAuthorship W2023755744A5047726859 @default.
- W2023755744 hasAuthorship W2023755744A5060181258 @default.
- W2023755744 hasConcept C126322002 @default.
- W2023755744 hasConcept C151730666 @default.
- W2023755744 hasConcept C164705383 @default.
- W2023755744 hasConcept C27016395 @default.
- W2023755744 hasConcept C2778198053 @default.
- W2023755744 hasConcept C2778213512 @default.
- W2023755744 hasConcept C2779200603 @default.
- W2023755744 hasConcept C2779343474 @default.
- W2023755744 hasConcept C2779611605 @default.
- W2023755744 hasConcept C500558357 @default.
- W2023755744 hasConcept C71924100 @default.
- W2023755744 hasConcept C84393581 @default.
- W2023755744 hasConcept C86803240 @default.
- W2023755744 hasConceptScore W2023755744C126322002 @default.
- W2023755744 hasConceptScore W2023755744C151730666 @default.
- W2023755744 hasConceptScore W2023755744C164705383 @default.
- W2023755744 hasConceptScore W2023755744C27016395 @default.
- W2023755744 hasConceptScore W2023755744C2778198053 @default.
- W2023755744 hasConceptScore W2023755744C2778213512 @default.
- W2023755744 hasConceptScore W2023755744C2779200603 @default.
- W2023755744 hasConceptScore W2023755744C2779343474 @default.
- W2023755744 hasConceptScore W2023755744C2779611605 @default.
- W2023755744 hasConceptScore W2023755744C500558357 @default.
- W2023755744 hasConceptScore W2023755744C71924100 @default.
- W2023755744 hasConceptScore W2023755744C84393581 @default.
- W2023755744 hasConceptScore W2023755744C86803240 @default.
- W2023755744 hasIssue "9535" @default.
- W2023755744 hasLocation W20237557441 @default.
- W2023755744 hasLocation W20237557442 @default.
- W2023755744 hasOpenAccess W2023755744 @default.
- W2023755744 hasPrimaryLocation W20237557441 @default.
- W2023755744 hasRelatedWork W1864361583 @default.
- W2023755744 hasRelatedWork W2104371670 @default.
- W2023755744 hasRelatedWork W2335083084 @default.
- W2023755744 hasRelatedWork W2403278124 @default.
- W2023755744 hasRelatedWork W2411207201 @default.
- W2023755744 hasRelatedWork W2417414779 @default.
- W2023755744 hasRelatedWork W2790353319 @default.
- W2023755744 hasRelatedWork W2964563167 @default.
- W2023755744 hasRelatedWork W4252783139 @default.
- W2023755744 hasRelatedWork W2523665804 @default.
- W2023755744 hasVolume "368" @default.
- W2023755744 isParatext "false" @default.
- W2023755744 isRetracted "false" @default.
- W2023755744 magId "2023755744" @default.
- W2023755744 workType "article" @default.